SciBase Gets Expanded FDA Approval

SciBase, a developer of AI-based skin disorder diagnostics, has received FDA approval for extended labeling in the U.S. The approval allows a wider range of healthcare professionals to use its AI diagnostic solutions, potentially broadening the technology's market access and adoption.

SciBase's core technology, Electrical Impedance Spectroscopy (EIS), distinguishes it from competitors focused on visual analysis. The Nevisense platform uses a probe with a disposable electrode to send small electrical signals into the skin, with the AI analyzing cellular structure based on impedance measurements, creating a recurring revenue model from

Get your own daily briefing

Scout delivers personalized news, insights, and conversations tailored to your role and industry.

Download on the App Store

Shared from Scout - Be the smartest in the room.